AbbVie Inc. (ABBV)
AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe
The European Commission approves ABBV's Elahere for the treatment of platinum-resistant ovarian cancer.
High-Conviction Investing - 4 Of The Best Dividend Stocks Money Can Buy
The current market presents a complex mix of opportunities and risks, influenced by the Trump presidency, Fed policies, and elevated valuations. These factors require careful stock selection. I am focusing on sectors with strong recovery potential and long-term tailwinds, such as transportation and defense, while considering valuation and growth potential. My picks include high-quality, dividend-paying stocks positioned for growth, pricing power, and resilience, making them ideal investments for a volatile market.
Why This Beaten-Down Dividend Stock Is a No-Brainer Buy on the Dip
Why This Beaten-Down Dividend Stock Is a No-Brainer Buy on the Dip
Can This Dividend King Ever Hit $400 After This Major Fail?
Pharmaceutical giant AbbVie (NYSE:ABBV) has suffered a meltdown over the past week, with shares losing 15% of their value.
AbbVie Stock Falls 11% in a Month: Should You Buy the Dip?
Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.
Got $1,500 to Invest? AbbVie Just Proved the Bull Thesis for Its Stock
The drugmaker has convincingly laid to rest the biggest threat to its top line.
Final Trades: Bitcoin, Abbvie and Baker Hughes
The Investment Committee reveals their final trades for today.
2 Dividend Stocks to Buy Hand Over Fist in November
These companies have solid businesses and excellent dividend growth track records.
Aldeyra's FDA Resubmission And AbbVie Option Revitalize Reproxalap's Prospects
Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. AbbVie entered an option agreement with Aldeyra, potentially licensing reproxalap for global markets. Aldeyra conducted a Phase 3 trial, where reproxalap met its primary endpoint in DED patients.
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
On Monday, AbbVie Inc ABBV stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials.
AbbVie's loss is Bristol Myers Squibb's gain - analyst
Recent trial failures over at pharma giant AbbVie Inc have created a window of opportunity for competitor Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP), is analysts at UBS are to be believed. AbbVie stock took a $38 billion hit on Monday after the company revealed that Phase 2 trials of its emraclidine schizophrenia treatment have failed to meet their primary endpoint objectives.
